Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 4/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27312174 | 1.00 | UCHL1 (0.49) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL31166697 | 1.00 | UCHL1 (0.49) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL27306156 | 1.00 | UCHL1 (0.49) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL31166699 | 0.94 | UCHL1 (0.42) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL17631792 | 0.90 | UCHL1 (0.47) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL17631797 | 0.90 | UCHL1 (0.47) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL31166705 | 0.88 | UCHL1 (0.49) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL27306151 | 0.88 | UCHL1 (0.49) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL30513241 | 0.83 | UCHL1 (0.46) | UCHL1USP30MAPTMEN1KMT2A | |
| SCHEMBL17631922 | 0.83 | UCHL1 (0.46) | UCHL1USP30MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335427-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335427-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | JAK1, JAK2, UBQLN1 | UCHL1 148/4885USP30 12/4885MAPT 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.